Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.67 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.66 |
| ▸ | DRD4 | P21917 | 4/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | CCR2 | P41597 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | DRD5 | P21918 | 1/20 | 0.59 |
| ▸ | CCR8 | P51685 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725665 | 0.86 | DRD4 (0.60) | SIGMAR1MCHR1DRD4DRD2HTR2A | |
| SCHEMBL31616410 | 0.83 | DCUN1D1 (0.66) | SIGMAR1MCHR1DRD4DRD2ALDH1A1 | |
| SCHEMBL31616337 | 0.83 | DCUN1D1 (0.66) | SIGMAR1MCHR1DRD4DRD2ALDH1A1 | |
| SCHEMBL31616451 | 0.83 | DCUN1D1 (0.66) | SIGMAR1MCHR1DRD4DRD2ALDH1A1 | |
| SCHEMBL17961749 | 0.82 | DRD4 (0.70) | SIGMAR1MCHR1DRD4DRD2KMT2A | |
| SCHEMBL19614234 | 0.82 | DRD4 (0.70) | SIGMAR1MCHR1DRD4DRD2KMT2A | |
| SCHEMBL20183285 | 0.82 | DRD4 (0.70) | SIGMAR1MCHR1DRD4DRD2KMT2A | |
| SCHEMBL22716943 | 0.82 | SIGMAR1 (0.67) | SIGMAR1MCHR1DRD4DRD2CCR2 | |
| SCHEMBL22716944 | 0.82 | SIGMAR1 (0.67) | SIGMAR1MCHR1DRD4DRD2CCR2 | |
| SCHEMBL4215311 | 0.82 | DRD4 (0.65) | SIGMAR1MCHR1DRD4DRD2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | SIGMAR1 1585/4885MCHR1 997/4885DRD4 3176/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | SIGMAR1 1514/4885MCHR1 1149/4885DRD4 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.